首页> 外文期刊>Journal of pediatric oncology nursing: official journal of the Association of Pediatric Oncology Nurses >Examining the push-pull method of blood sampling from central venous access devices.
【24h】

Examining the push-pull method of blood sampling from central venous access devices.

机译:检查从中央静脉通路设备抽取血液的推挽方法。

获取原文
获取原文并翻译 | 示例
           

摘要

The placement of a central venous access device (CVAD) has revolutionized supportive care for pediatric cancer patients. The CVAD is used to administer chemotherapy/biotherapy, blood products, total parenteral nutrition, antibiotics, and many other supportive medications. CVADs also provide the ability to obtain blood samples without the trauma associated with venipuncture. Frequent blood sampling is often needed to monitor the side effects and response of the cancer treatment. Unfortunately, the most common method requires discarding blood (0.5-10 mL, depending on the institution's protocol) with each lab draws, for various reasons. For pediatric oncology patients, this can result in a large volume of blood being discarded and subsequently increase the need for blood transfusions. Repeated exposure to allogeneic (donor) blood products can put this patient population at additional risk for alloimmunization and febrile reactions. The purpose of this study is to test the limits of agreement between laboratory values (chemistry panel 18 and complete blood count) obtained using the push-pull and standard methods of blood sampling from CVADs in pediatric oncology patients.
机译:中央静脉通路设备(CVAD)的放置彻底改变了对小儿癌症患者的支持治疗。 CVAD用于管理化学疗法/生物疗法,血液制品,全胃肠外营养,抗生素和许多其他支持药物。 CVAD还提供了获取血液样本的能力,而不会造成与静脉穿刺相关的创伤。通常需要经常抽血以监测癌症治疗的副作用和反应。不幸的是,由于各种原因,每次实验室抽血时,最常用的方法都需要丢弃血液(0.5-10 mL,取决于医疗机构的规程)。对于小儿肿瘤科患者,这可能导致大量血液被丢弃,从而增加了输血的需要。反复接触同种异体(供体)血液制品可能会使该患者群体面临同种免疫和发热反应的额外风险。这项研究的目的是测试使用推挽法和标准方法从儿科肿瘤患者的CVAD采血中获得的实验室值(化学成分18和全血细胞计数)之间的一致性极限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号